Oric Pharmaceuticals IncNASDAQ:ORIC
- LAST PRICE7.2650
- TODAY'S CHANGE (%)0.2550 (3.6377%)
- Bid / Lots7.2500/ 14
- Ask / Lots7.2800/ 5
- Open / Previous Close7.0700 / 7.0100
- Day Range
- 52 Week Range
- Volume256,610
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORIC |
|---|---|---|
| 09:32 ET | 66493 | 7.31 |
| 09:41 ET | 600 | 7.17 |
| 09:50 ET | 116 | 7.22 |
| 09:54 ET | 2600 | 7.03 |
| 09:59 ET | 250 | 7.02 |
| 10:03 ET | 641 | 7 |
| 10:08 ET | 500 | 7.03 |
| 10:12 ET | 100 | 7 |
| 10:14 ET | 217 | 7.03 |
| 10:15 ET | 200 | 7.07 |
| 10:17 ET | 700 | 7.055 |
| 10:26 ET | 100 | 7.065 |
| 10:30 ET | 100 | 7.07 |
| 10:32 ET | 500 | 7.04 |
| 10:33 ET | 700 | 7.09 |
| 10:37 ET | 400 | 7.108 |
| 10:39 ET | 500 | 7.09 |
| 10:42 ET | 600 | 7.09 |
| 10:44 ET | 708 | 7.12 |
| 10:46 ET | 200 | 7.13 |
| 10:48 ET | 1819 | 7.14 |
| 10:50 ET | 400 | 7.18 |
| 10:51 ET | 732 | 7.2 |
| 10:55 ET | 220 | 7.19 |
| 10:57 ET | 600 | 7.18 |
| 11:02 ET | 400 | 7.195 |
| 11:04 ET | 100 | 7.21 |
| 11:06 ET | 800 | 7.185 |
| 11:08 ET | 100 | 7.2 |
| 11:09 ET | 300 | 7.18 |
| 11:11 ET | 400 | 7.18 |
| 11:13 ET | 1000 | 7.14 |
| 11:15 ET | 14580 | 7.17 |
| 11:18 ET | 876 | 7.18 |
| 11:20 ET | 300 | 7.23 |
| 11:22 ET | 825 | 7.23 |
| 11:24 ET | 526 | 7.24 |
| 11:26 ET | 100 | 7.25 |
| 11:27 ET | 290 | 7.269 |
| 11:29 ET | 338 | 7.26 |
| 11:31 ET | 1549 | 7.25 |
| 11:36 ET | 3395 | 7.2501 |
| 11:38 ET | 100 | 7.24 |
| 11:40 ET | 500 | 7.27 |
| 11:42 ET | 393 | 7.26 |
| 11:44 ET | 1480 | 7.21 |
| 11:45 ET | 100 | 7.19 |
| 11:54 ET | 173 | 7.18 |
| 11:58 ET | 119 | 7.2 |
| 12:00 ET | 400 | 7.2 |
| 12:02 ET | 200 | 7.17 |
| 12:14 ET | 200 | 7.13 |
| 12:20 ET | 3840 | 7.05 |
| 12:21 ET | 2076 | 7.13 |
| 12:23 ET | 150 | 7.13 |
| 12:27 ET | 7758 | 7.19 |
| 12:30 ET | 492 | 7.2 |
| 12:32 ET | 100 | 7.2 |
| 12:34 ET | 648 | 7.21 |
| 12:36 ET | 617 | 7.22 |
| 12:38 ET | 700 | 7.21 |
| 12:39 ET | 100 | 7.2 |
| 12:45 ET | 667 | 7.2 |
| 12:52 ET | 100 | 7.21 |
| 12:54 ET | 100 | 7.22 |
| 12:56 ET | 100 | 7.25 |
| 12:59 ET | 1099 | 7.24 |
| 01:01 ET | 200 | 7.225 |
| 01:06 ET | 200 | 7.22 |
| 01:08 ET | 424 | 7.23 |
| 01:12 ET | 800 | 7.24 |
| 01:14 ET | 100 | 7.21 |
| 01:17 ET | 200 | 7.21 |
| 01:19 ET | 100 | 7.21 |
| 01:21 ET | 300 | 7.2 |
| 01:24 ET | 200 | 7.17 |
| 01:28 ET | 200 | 7.21 |
| 01:32 ET | 300 | 7.17 |
| 01:33 ET | 6746 | 7.25 |
| 01:35 ET | 709 | 7.27 |
| 01:37 ET | 794 | 7.25 |
| 01:39 ET | 820 | 7.23 |
| 01:42 ET | 225 | 7.225 |
| 01:44 ET | 700 | 7.22 |
| 01:46 ET | 1152 | 7.23 |
| 01:48 ET | 400 | 7.225 |
| 01:50 ET | 1313 | 7.25 |
| 01:51 ET | 127 | 7.25 |
| 01:53 ET | 200 | 7.24 |
| 01:55 ET | 100 | 7.26 |
| 01:57 ET | 100 | 7.24 |
| 02:00 ET | 100 | 7.25 |
| 02:02 ET | 1320 | 7.24 |
| 02:04 ET | 200 | 7.24 |
| 02:08 ET | 100 | 7.21 |
| 02:09 ET | 400 | 7.225 |
| 02:13 ET | 200 | 7.22 |
| 02:15 ET | 200 | 7.25 |
| 02:18 ET | 756 | 7.25 |
| 02:20 ET | 913 | 7.21 |
| 02:24 ET | 100 | 7.22 |
| 02:27 ET | 220 | 7.22 |
| 02:29 ET | 278 | 7.22 |
| 02:33 ET | 500 | 7.185 |
| 02:38 ET | 1254 | 7.15 |
| 02:40 ET | 100 | 7.14 |
| 02:44 ET | 533 | 7.14 |
| 02:47 ET | 1166 | 7.16 |
| 02:49 ET | 1322 | 7.17 |
| 02:51 ET | 500 | 7.17 |
| 02:54 ET | 102 | 7.1708 |
| 02:58 ET | 353 | 7.18 |
| 03:02 ET | 2078 | 7.16 |
| 03:03 ET | 200 | 7.16 |
| 03:05 ET | 222 | 7.17 |
| 03:07 ET | 357 | 7.17 |
| 03:12 ET | 2796 | 7.2 |
| 03:16 ET | 100 | 7.2 |
| 03:18 ET | 100 | 7.19 |
| 03:20 ET | 1269 | 7.21 |
| 03:21 ET | 1520 | 7.22 |
| 03:23 ET | 200 | 7.22 |
| 03:27 ET | 2907 | 7.22 |
| 03:30 ET | 2104 | 7.23 |
| 03:32 ET | 1500 | 7.2 |
| 03:34 ET | 1014 | 7.21 |
| 03:36 ET | 400 | 7.21 |
| 03:38 ET | 1398 | 7.2 |
| 03:39 ET | 1785 | 7.22 |
| 03:41 ET | 1000 | 7.23 |
| 03:43 ET | 1522 | 7.27 |
| 03:45 ET | 3205 | 7.26 |
| 03:48 ET | 3198 | 7.265 |
Jun 7, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Jun 07, 2024 by Dow Jones
4:30PM ET on Friday Jun 07, 2024 by Dow Jones
May 29, 2024
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences, from 4:30PM ET on Wednesday May 29, 2024 by Dow Jones
4:30PM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oric Pharmaceuticals Inc | 472.6M | -4.0x | --- |
Kalvista Pharmaceuticals Inc | 472.9M | -3.7x | --- |
Erasca Inc | 483.1M | -2.5x | --- |
LENZ Therapeutics Inc | 461.2M | -1.2x | --- |
Larimar Therapeutics Inc | 484.3M | -8.4x | --- |
Astria Therapeutics Inc | 484.9M | -4.0x | --- |
Company Information
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Contact Information
- Headquarters
- 240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-388-5600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Heyman
- President, Chief Executive Officer, Director
- Jacob Chacko
- Chief Financial Officer
- Dominic Piscitelli
- Chief Medical Officer
- Pratik Multani
- Independent Director
- Mardi Dier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $472.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-1.81 |
Book Value | $4.08 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
